The ratings of seven biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Epizyme, Inc. (EPZM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Equity, EPZM also gets F’s. The stock’s trailing PE Ratio is 452.00. To get an in-depth look at EPZM, get Portfolio Grader’s complete analysis of EPZM stock.
Kindred Biosciences, Inc. (KIN) earns a D this week, moving down from last week’s grade of C. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of KIN stock.
This week, Trius Therapeutics, Inc. (TSRX) drops from a C to a D rating. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
The rating of Vical Incorporated (VICL) slips from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.
This week, Grifols, S.A. Sponsored ADR Class B’s (GRFS) rating worsens to a D from the company’s C rating a week ago. Grifols develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. The stock also rates an F in Earnings Surprise. To get an in-depth look at GRFS, get Portfolio Grader’s complete analysis of GRFS stock.
Array BioPharma (ARRY) is having a tough week. The company’s rating falls from a C to a D. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The stock gets F’s in Cash Flow and Sales Growth. As of Jan. 13, 2015, 14.1% of outstanding Array BioPharma shares were held short. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Tenax Therapeutics, Inc.’s (TENX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). The stock receives F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The stock has a trailing PE Ratio of 121.70. To get an in-depth look at TENX, get Portfolio Grader’s complete analysis of TENX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
